AndroGel in Men 65 and Older: What the Evidence Actually Shows

What FDA Labeling Actually Says About Older Men

The FDA-approved prescribing information for AndroGel does not set a maximum age for use. It approves the drug for adult males with hypogonadism caused by primary testicular failure or hypothalamic-pituitary dysfunction. Age-related testosterone decline, sometimes called late-onset hypogonadism or andropause, is a distinct physiological process and is not listed as an approved indication in the current label reviewed by the FDA [1].

Because the label does not name geriatric patients as a separate approved population, any prescribing specifically to address age-associated testosterone decline in men 65 and older is considered off-label. That distinction matters for informed consent, insurance coverage, and liability.

How the Label Addresses Geriatric Pharmacology

The AndroGel 1.62% prescribing information notes that clinical studies did not include enough subjects aged 65 and older to determine whether they respond differently from younger adults [1]. This absence of geriatric-specific safety data is itself a regulatory signal. The FDA requires labeling to disclose when data are insufficient to characterize a subgroup, and that disclosure shifts the evidentiary burden to post-marketing research.

What "Off-Label" Means Practically

Off-label prescribing is legal and common in the United States. Roughly 20% of all prescription drug use in outpatient settings is off-label, according to data published in JAMA Internal Medicine [2]. A physician who prescribes AndroGel to a 70-year-old man with confirmed low testosterone and symptoms is practicing within the law, but should document the clinical rationale, discuss the evidence base with the patient, and obtain informed consent acknowledging that long-term safety data in this age group remain limited [2].

Why Testosterone Falls After 65 and Why That Complicates Treatment Decisions

Total serum testosterone declines at roughly 1 to 2% per year after age 30, and free testosterone falls faster because sex hormone-binding globulin rises with age [3]. By age 70, an estimated 20 to 30% of men have total testosterone below 300 ng/dL, the threshold most guidelines use to define biochemical hypogonadism [3].

The clinical problem is separating true hypogonadism from normal aging. Symptoms such as fatigue, reduced libido, and decreased muscle mass occur in many older men regardless of testosterone level, making biochemical confirmation essential before starting any testosterone therapy.

Diagnosing Hypogonadism in Older Men: The Two-Sample Rule

The Endocrine Society's 2018 Clinical Practice Guideline specifies that hypogonadism should be confirmed on at least two separate morning fasting samples, ideally measured by liquid chromatography-tandem mass spectrometry rather than immunoassay, which overestimates levels in older men [4]. A single low value is insufficient for diagnosis, particularly in men over 65, because acute illness, poor sleep, or obesity can transiently suppress testosterone without representing true hypogonadal disease [4].

Calculated Free Testosterone

When total testosterone falls in a gray zone (roughly 200 to 400 ng/dL), calculated free testosterone using the Vermeulen equation adds diagnostic precision. The Endocrine Society guideline recommends measuring albumin and SHBG alongside total testosterone when the clinical picture is uncertain [4]. Free testosterone below 65 pg/mL is generally considered low in the context of suggestive symptoms [4].

The Testosterone Trials: The Best Evidence We Have

The TTrials (Testosterone Trials) are the most rigorous data set available for testosterone therapy in older men. Funded by the National Institutes of Health, the TTrials enrolled 788 men aged 65 and older with total testosterone below 275 ng/dL and at least one symptom cluster (sexual dysfunction, low vitality, or poor physical function) [5]. Participants were randomized to testosterone gel titrated to maintain levels between 500 and 1,000 ng/dL or to placebo gel for 12 months [5].

Sexual Function Domain Results

The sexual activity sub-trial showed statistically significant improvement in sexual desire, erectile function, and overall sexual activity scores in the testosterone arm compared with placebo [5]. The between-group difference in the PDAS (Psychosexual Daily Questionnaire) sexual activity domain score was 0.58 points (P<0.001) [5]. That improvement is real but modest in absolute magnitude.

Physical Function and Vitality

Physical function scores and walking distance did not improve significantly in the testosterone group compared with placebo over 12 months [5]. Vitality scores improved, but the effect size was small. These null or marginal findings for function and energy are important: they argue against broad prescribing to older men primarily seeking improved strength or stamina.

Bone Density Results

A separate TTrials sub-study (N=211) examined bone mineral density. Volumetric bone mineral density of the spine increased by 7.5% in the testosterone arm vs. 0.8% in placebo (P<0.001), and estimated bone strength also improved significantly [6]. This bone benefit may be meaningful for men with osteoporosis, though fracture endpoint data from testosterone trials remain sparse.

The Cardiovascular Plaque Signal

The most concerning TTrials finding appeared in the CATH sub-study (N=138), which used coronary CT angiography. Noncalcified coronary artery plaque volume increased by a mean of 41% more in the testosterone group than in placebo over 12 months (P=0.002) [7]. Noncalcified plaque is considered more vulnerable to rupture than calcified plaque, making this finding clinically relevant even though the trial was not powered to detect myocardial infarction events. The lead investigators published these results in JAMA [7].

FDA Safety Communications and Post-Marketing Surveillance

The FDA issued a drug safety communication in 2015 requiring all testosterone products to carry labeling updates warning about the risk of venous thromboembolism and about reports of serious cardiovascular events [8]. The agency also required a label change noting that testosterone products should be used only for classical hypogonadism confirmed by laboratory testing, explicitly discouraging use for age-related testosterone decline [8].

A 2016 FDA advisory committee reviewed observational data and found conflicting results across studies, with some showing increased cardiovascular event rates in older men initiated on testosterone and others showing neutral or slightly protective associations [8]. The committee did not conclude that testosterone therapy is definitively cardiotoxic, but it supported the labeling language requiring confirmed biochemical hypogonadism before prescribing.

The TRAVERSE Trial (2023)

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, enrolled 5,204 middle-aged and older men (mean age 63.5) with hypogonadism and pre-existing cardiovascular disease or elevated risk [9]. Testosterone gel use did not increase the rate of the primary composite MACE endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) compared with placebo over a median follow-up of 22 months (hazard ratio 0.96, 95% CI 0.78 to 1.17) [9]. Atrial fibrillation and acute kidney injury were more common in the testosterone arm [9]. TRAVERSE provides some reassurance on MACE but does not eliminate concern about atrial fibrillation or the plaque findings from TTrials.

Endocrine Society and Other Guideline Positions

The 2018 Endocrine Society Clinical Practice Guideline on Male Hypogonadism states: "We suggest against testosterone therapy in men who have age-related testosterone decline only, without biochemically confirmed hypogonadism" [4]. This is a Grade 2, Moderate evidence recommendation. The guideline supports testosterone therapy in older men with confirmed hypogonadism and symptoms, but recommends that clinicians "engage in a detailed discussion of the benefits and risks" before prescribing to any man over 65 [4].

The American Urological Association's 2022 guidelines align with this position, noting that testosterone therapy may be offered to symptomatic men with consistently low testosterone levels but should not be initiated in men with recent major adverse cardiac events, uncontrolled heart failure, or hematocrit above 54% [10].

A Practical Prescribing Framework for Men 65 and Older

Applying guideline language to clinical practice requires a structured approach. Based on the TTrials data, the Endocrine Society guideline, and the TRAVERSE findings, a reasonable decision pathway for men 65 and older includes:

1. Confirm testosterone below 300 ng/dL on two morning samples measured by mass spectrometry.
2. Identify at least one symptom domain (sexual function, energy, or bone loss) directly attributable to hypogonadism after excluding other causes.
3. Screen for contraindications: prostate cancer, breast cancer, erythrocytosis (hematocrit above 54%), severe untreated obstructive sleep apnea, heart failure (NYHA class III or IV), recent MI or stroke within 6 months, desire for fertility.
4. Obtain baseline labs: complete blood count, PSA, lipid panel, liver function, serum testosterone.
5. Start at the lowest effective dose and recheck testosterone at 14 days, then full labs at 3 months.

Dosing AndroGel in Older Adults

AndroGel 1.62% starts at 40.5 mg (two pump actuations or one 40.5 mg packet) applied to the upper arms and shoulders once daily in the morning [1]. After 14 days, check serum testosterone. Titrate to 20.25 mg (one actuation) if levels exceed 1,000 ng/dL, or increase to 60.75 mg (three actuations) if levels remain below 300 ng/dL with ongoing symptoms [1].

AndroGel 1% starts at 50 mg daily (five gram packet or pump). The maximum dose is 100 mg daily [1].

Application and Transfer Risk

Testosterone gel transfers to others through skin-to-skin contact. For older men living with grandchildren or female partners, this risk requires explicit counseling. The FDA label requires patients to cover the application site with clothing after the gel dries and wash hands thoroughly [1]. Accidental transfer to children has caused virilization, a serious adverse event documented in post-marketing reports reviewed by the FDA [8].

Monitoring Parameters in Men 65 and Older

Older men require closer monitoring than younger adults due to higher baseline cardiovascular risk and greater susceptibility to erythrocytosis. Recommended monitoring intervals based on Endocrine Society guidance [4]:

| Parameter | Timing | |---|---| | Serum testosterone | 14 days after initiation or dose change, then every 3 to 6 months | | Hematocrit | Baseline, then 3 months, then annually | | PSA | Baseline, then 3 months, then per AUA prostate cancer screening guidelines | | Lipid panel | Baseline, then 12 months | | Bone mineral density | Baseline DXA if osteoporosis risk is present; repeat at 1 to 2 years |

If hematocrit rises above 54%, the dose should be reduced or therapy held until hematocrit normalizes, then restarted at a lower dose [4]. Erythrocytosis occurs more frequently in older men, partly due to reduced plasma volume and reduced erythropoietin clearance.

Risks Specific to the 65-Plus Population

Erythrocytosis

Testosterone stimulates erythropoiesis via erythropoietin and direct effects on bone marrow. In the TTrials, hematocrit rose above 54% in 5.9% of testosterone-treated men vs. 0% in placebo [5]. Older men with baseline hematocrit above 50%, sleep apnea, or chronic lung disease are at greatest risk. Erythrocytosis increases blood viscosity and raises the risk of venous thromboembolism and stroke [4].

Prostate Safety

Testosterone therapy does not appear to cause prostate cancer de novo based on current evidence, but it can stimulate growth in subclinical disease. The TTrials showed no statistically significant difference in prostate cancer incidence between groups over 12 months, though the follow-up period was too short to detect slow-growing tumors [5]. PSA should be checked at 3 months; a rise of more than 1.4 ng/mL above baseline within the first 12 months of therapy warrants urology referral [4].

Falls and Sleep Apnea

Testosterone therapy may worsen obstructive sleep apnea by altering upper airway muscle tone and ventilatory drive. Men 65 and older have higher baseline rates of sleep apnea, and initiating therapy without screening for this condition adds risk. Uncontrolled moderate-to-severe sleep apnea is listed as a relative contraindication in the Endocrine Society guideline [4]. New or worsening apnea symptoms after starting AndroGel should prompt sleep study referral before continuing therapy.

What Older Men Realistically Gain From AndroGel

The evidence supports a clear benefit in one domain: sexual function. The TTrials sexual sub-trial found improvement in sexual desire and activity that was statistically significant and sustained at 12 months [5]. For men 65 and older with confirmed hypogonadism and sexual dysfunction as a primary complaint, that benefit is real and clinically meaningful.

Bone density improves with testosterone therapy, and this may reduce fracture risk over time, though fracture endpoint data are not yet available from randomized trials of adequate size [6].

Physical function, vitality, and cognitive performance showed modest or null effects in TTrials, which enrolled a population specifically selected for low testosterone and symptoms. Expecting broad improvements in energy, strength, or mood without confirmed hypogonadism is not supported by the data.

Atrial Fibrillation: A Closer Look at TRAVERSE

In TRAVERSE, atrial fibrillation occurred in 3.5% of the testosterone group vs. 2.4% in placebo, a statistically significant difference (hazard ratio 1.88, P=0.001) [9]. Older men already carry higher baseline rates of atrial fibrillation, and adding testosterone to that risk profile deserves explicit discussion during informed consent. Men with prior atrial fibrillation, structural heart disease, or age above 75 may face disproportionate risk.